Vasocure is a vascular therapeutics enterprise in clinical development that uses a peptide to treat neointimal disease and atherosclerosis. They’re a pharmaceutical firm with nephrology, cardiology, and oncology candidates. Their precision medicine approach to creating pedifin will employ a predictive clinical strategy to identify the optimum treatment delivery. They believe a new approach is needed, and the pedifin medication treats neointimal illness and gives hope to people with kidney failure.
